Toulouse, France, October 17, 2021 – GTP Nano, a contract development and manufacturing organization (CDMO) serving the pharmaceutical industry, announced the production of its first clinical batches at its Toulouse, France plant. A new entrant on the nanodrug market, GTP Nano is leveraging an original partnership with research organization CEA that includes ongoing support with nanoformulation and the development of the associated manufacturing processes, as well as with nanocharacterization.
The nanovectorization of drugs, now used in certain precision therapies, has been the subject of pharmaceutical research and development for more than two decades. The technology has the capacity to transport drugs directly to where they are needed and gradually release the active ingredients, substantially increasing efficacy while reducing undesirable side effects. The global nanomedicine market is expected to be worth hundreds of billions of dollars by 2025, with the therapeutics segment forecasted to expand at an 8.3% compound annual growth rate (CAGR) over the next five years (sources: Market Data Forecast and Mordor Intelligence).
